PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-12.98%
Revenue decline while Drug Manufacturers - Specialty & Generic median is -8.52%. Seth Klarman would investigate if market share loss is temporary.
-15.76%
Cost reduction while Drug Manufacturers - Specialty & Generic median is -10.29%. Seth Klarman would investigate competitive advantage potential.
-5.67%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is -5.67%. Seth Klarman would investigate competitive position.
8.39%
Margin expansion exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.01%. Joel Greenblatt would investigate competitive advantages.
-73.35%
R&D reduction while Drug Manufacturers - Specialty & Generic median is -5.20%. Seth Klarman would investigate competitive implications.
-7.64%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
-9.84%
Marketing expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
154.29%
Other expenses change of 154.29% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
14.76%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.63%. Jim Chanos would check for waste.
-5.54%
Total costs reduction while Drug Manufacturers - Specialty & Generic median is -6.62%. Seth Klarman would investigate advantages.
-55.84%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is -5.31%. Seth Klarman would investigate advantages.
0.26%
D&A growth while Drug Manufacturers - Specialty & Generic reduces D&A. Peter Lynch would examine asset strategy.
-28.36%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is -14.34%. Seth Klarman would investigate causes.
-18.55%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is -7.65%. Seth Klarman would investigate causes.
-77.54%
Operating income decline while Drug Manufacturers - Specialty & Generic median is -9.71%. Seth Klarman would investigate causes.
-104.02%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is -8.44%. Seth Klarman would investigate causes.
113.69%
Other expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.34%. Jim Chanos would check for issues.
21.48%
Pre-tax income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
9.77%
Margin change of 9.77% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
103.21%
Tax expense change of 103.21% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify strategy.
-23.37%
Net income decline while Drug Manufacturers - Specialty & Generic median is -10.25%. Seth Klarman would investigate causes.
-41.77%
Net margin decline while Drug Manufacturers - Specialty & Generic median is -2.09%. Seth Klarman would investigate causes.
-11.75%
EPS decline while Drug Manufacturers - Specialty & Generic median is -10.03%. Seth Klarman would investigate causes.
-11.75%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is -10.03%. Seth Klarman would investigate causes.
10.30%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.12%. Jim Chanos would check for issues.
10.30%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.09%. Jim Chanos would check for issues.